Variant Creutzfeldt-Jakob disease (vCJD) was first described in the United Kingdom in 1996 and is thought to have been transmitted from cattle infected with bovine spongiform encephalopathy probably via the food chain. Thus far just over 100 definite or probable clinical cases have been described, though the number of people currently infected and the eventual size and geographic distribution of any future clinical epidemic remain uncertain. There is little evidence that sporadic CJD is transmitted by blood transfusion. However, the same cannot necessarily be assumed to apply to the new variant strain of disease in which involvement of peripheral lymphoid tissues has been demonstrated. In the face of uncertainty surrounding the risk of transmission of vCJD by blood products, blood transfusion services in a number of countries have implemented precautionary policies, though whether in the long term these will prove to have been necessary or sufficient remains to be seen. Variant Creutzfeldt-Jakob disease (vCJD) is a new form of human transmissible spongiform encephalopathy which first appeared in the United Kingdom (UK) in 1994 [1] . The clinical features differ from those of sporadic CJD. Patients are younger, with a median age of 29 years. Three of the UK cases have been children younger than 16 years of age, with the youngest being 12 at disease onset [2] . A case has recently been described in a 74-year-old man [3] . Patients seek treatment for neuropsychiatric symptoms and sensory disturbance and progress to ataxia, involuntary movements, and cognitive impairment during a period of 7 to 38 months [4] [5] [6] . The early symptoms of the disease can be relatively nonspecific, and currently there are no noninvasive diagnostic tests available [7] . Electroencephalography does not detect the typical features found in sporadic CJD. The cerebrospinal fluid shows increased levels of 14-3-3 and other nonspecific markers of central nervous system damage in a proportion of clinical cases. Recently the presence of bilateral high signals on T2 (proton density)weighted images of the posterior thalamus (the pulvinar) on magnetic resonance imaging of the brain has been shown in appropriate clinical context to be 78% sensitive and 95% specific for vCJD [8] . Standard clinical diagnostic criteria have now been formulated that should allow clinical diagnosis of suspect cases with a relatively high degree of confidence [9•].
Neuropathologic examination is mandatory for confirmation of a diagnosis of vCJD. The characteristic feature of this disease is the presence of large numbers of florid amyloid plaques, each surrounded by a zone of spongiform change [10•]. Immunocytochemistry shows widespread accumulation of prion protein (PrP) in the brain. Abnormal accumulation of PrP has also been identified in follicular dendritic cells within the germinal centers of the tonsil; appendix; spleen; gut-associated lymphoid tissue in the ileum; and cervical, mediastinal, para-aortic, and mesenteric lymph nodes [11, 12] . In one patient, abnormal PrP deposition was identified in the appendix, which was removed 8 months before the onset of clinical disease [11] . Biochemical studies reveal that patients with vCJD show a predominance of the diglycosylated form of protease-resistant prion protein (PrP Sc ) in both the central nervous system and peripheral lymphoid tissues [13] .
The combination of clinical, epidemiologic, and neuropathologic features outlined above allows clear distinction between variant and other forms of CJD and is con-sistent with a single strain of causal agent. Moreover, it suggests that vCJD is related to bovine spongiform encephalopathy (BSE), more than 180,000 cases of which have occurred in the UK as of December 2000 [14•,15,16,17•] . The incidence of the disease continues to decline. There were just over 1,300 confirmed new cases in the UK during 2000, which was 40% lower than in 1999. However there are concerns over the possibility of continuing vertical or horizontal transmission of BSE among cattle and the possibility of transmission to sheep, where the disease may be difficult to discriminate from natural scrapie. Approximately 1,500 cases of BSE have occurred in other European countries that imported cattle or livestock feed supplements from the UK [17•]. Analyses of the glycosylation pattern of PrP Sc and the incubation periods and pattern of neuropathologic lesions in inbred strains of laboratory mice have provided strong experimental support for the proposition that vCJD and BSE are the same strain of disease [18] [19] [20] [21] [22] . There is no direct experimental evidence that BSE can be orally transmitted to humans, and a recent case control study failed to identify any specific dietary risk factors for vCJD [23] . However, given the methodologic limitations inherent in these kinds of studies, the proposition that vCJD has arisen due to the transmission of BSE to humans via infected bovine food products is widely accepted. The future magnitude and geographic distribution of vCJD in countries such as the UK which have endogenous BSE or those which have imported infected cattle or bovine products remains uncertain. The possibility that large numbers of healthy people may currently be incubating the disease raises concerns over the possibility of transmission by surgical and diagnostic medical procedures, blood products, and organ and tissue transplantation [17•].
Peripheral pathogenesis of variant Creutzfeldt-Jakob disease
It has been known for many years that in experimental murine models, PrP Sc and infectivity can be detected in peripheral non-neural tissues [24•]. Early experiments demonstrated that after oral challenge with scrapie, infectivity is detectable in the lymphatic tissue associated with the gastrointestinal tract, and that after intraperitoneal inoculation infectivity is detectable in the spleen from as early as 1 week, rising to a plateau after 3 to 6 weeks and persisting thereafter throughout the course of the disease. Immunopotentiation by phytohemagglutinin is known to increase the efficiency of peripheral transmission of scrapie, whereas immunosuppression by steroids reduces that efficiency. Splenectomy also reduces transmission efficiency, whereas thymectomy and whole body sublethal ␥ irradiation have no effect [25] . Immunohistologic studies suggest that most PrP Sc accumulation occurs in follicular dendritic cells (FDCs) in the germinal centers.
More recently the role of the immune system in the pathogenesis of peripherally transmitted spongiform encephalopathies (TSEs) has been examined in detail using various strains of scrapie in inbred strains of knockout and immunodeficient mice. PrP-negative mice bearing PrP-positive cerebral neurografts have been shown to be resistant to peripheral but not central challenge. Similarly, mice with severe combined immunodeficiency, which lack B cells, T cells, and FDCs, are resistant to peripheral but not central challenge, though susceptibility is restored after allogeneic bone marrow transplantation. A series of experiments in knockout mice with deficiency of selected cellular components of their immune systems initially suggested that B cells were the essential component in peripheral disease transmission [26] . However, FDCs are dependent on B-cell signaling for survival, and subsequent studies have reinforced the primary role of the latter [27-33].
More recently, it has been shown that even temporary inactivation of FDCs after lymphotoxin-␤ receptor blockade abolishes splenic PrP Sc accumulation and retards neuroinvasion after peripheral challenge [34, 35] . Moreover, deficiencies of complement and complement receptors have also been shown to impede peripheral scrapie transmission [36, 37] . Therefore, it seems likely that after peripheral TSE challenge antibody-independent complement activation facilitates PrP Sc uptake by follicular dendritic cells, which go on to provide a critical reservoir of early PrP Sc replication [38] .
In scrapie-infected sheep, abnormal PrP accumulation is detectable on tonsillar biopsy from as early as 4 months of age and is predictive of the development of neurologic disease [39] . With the exception of a transient period of infectivity in the terminal ileum, lymphoid involvement does not appear to be a feature of BSE in cattle [40]. However, lymphoid involvement is a feature of BSE when transmitted to other animals, and in humans abnormal prion accumulation in FDCs in lymphoid tissue has been described in variant but not sporadic CJD [11, 12] .
There seems reason to surmise, therefore, that infectivity is likely to be present in the peripheral lymphoid systems of individuals infected with vCJD from the earliest phases of the disease. Whether this necessarily means that infectivity is present in the peripheral blood remains unclear.
Peripheral blood infectivity
No infectivity has ever been detected in the blood in natural scrapie in sheep and goats, transmissible mink encephalopathy in mink, or BSE in cattle. Infectivity is demonstrable in the peripheral blood of sheep and rodents experimentally infected with scrapie and BSE and in rodents experimentally infected with CJD during both the incubation and clinical phases of disease [41,42•]. The level of infectivity in the peripheral blood of TSEinfected rodents is approximately 5 to 10 iu/mL during the incubation period [43] [44] [45] , increasing to 100 iu/mL during the clinical phase of the disease. Studies in mice during the clinical phase of TSE from the Fukuoka 1 strain of human Gerstmann-Straussler-Scheinker syndrome demonstrated a fourfold higher concentration of infectivity in the buffy coat (containing the leukocytes and platelets) than in the plasma and no detectable infectivity in the red cells [43] . Subsequent studies in the same model have shown that blood taken during the preclinical incubation period shows a similar distribution of infectivity but much lower concentrations, and that transmission of disease by intravenous inoculation is 5 to 10 times less efficient than by intracerebral inoculation [44•]. Parallel studies in a scrapie-infected hamster model have produced similar findings [45, 46] .
Infectivity has also been demonstrated in the peripheral blood of mice experimentally infected with BSE [47] . It has recently been demonstrated that it is possible to transmit BSE from whole blood drawn from experimentally infected sheep during the preclinical phase of disease and infused intravenously into other sheep [48•]. Another recent study has demonstrated that intravenous administration is an efficient route of infection in cynomolgus monkeys [49] .
It has been observed, however, that the cellular distribution of PrP C expression varies between species and there are therefore some caveats about the extent to which animal models can be said to be representative of In humans, infectivity has been reported in the peripheral blood of 5 of 37 patients with sporadic CJD after intracerebral inoculation into rodents [42•]. However these studies are open to methodologic criticism, and no infectivity has been transmitted to primates by intracerebral inoculation of blood from patients with sporadic CJD. To date, vCJD has not been transmitted from human blood by intracerebral rodent or primate inoculation, though experiments are ongoing in several centers.
It remains unclear, therefore, whether infectivity is present in the peripheral blood of patients with vCJD. If it is, however, the titer is likely to be several orders of magnitude less than that found in the central nervous system and less during the incubation phase of the disease than the clinical phase. It also seems reasonable to conclude that infectivity is most likely to be concentrated in the buffy coat, with a lower concentration in the plasma and little associated with the red cells.
There are a handful of case reports in which clinical transmission of sporadic CJD by blood transfusion might have occurred. However, during the last 20 years, a series of epidemiologic case-control studies, lookback investigations of patients who have received blood components or plasma products from donors who later developed CJD, and surveillance studies of high-risk groups such as patients with hemophilia and congenital immunodeficiency syndromes have failed to show any substantive evidence of sporadic CJD transmission by blood transfusion [51, 52] . Thus, although the possibility that sporadic CJD is transmissible by blood transfusion cannot be formally excluded, it must be a rare event if it occurs at all. No evidence has yet come to light of vCJD transmission by blood components or products, however it is still early in the history of this disease and lookback and lookforward studies are ongoing.
Estimating the number of blood donors who may be incubating variant Creutzfeldt-Jakob disease
A key issue for blood transfusion services is an evaluation of the number of blood donors who could currently be infected with, and therefore in the preclinical phase of, vCJD. Thus far approximately 100 definite or probable vCJD cases have been described in the UK, with an additional 3 in France and 1 in Ireland. The Irish patient had lived in UK; however, none of the French patients had lived in or visited UK and so their infection is assumed to have come from cattle or beef products imported from the UK. The incidence of vCJD continues to increase, the number of disease onsets has risen by 23% per annum, and the number of deaths by 33% per annum between 1995 and 2000 [53, 54•] . No specific occupational, socioeconomic, or dietary risk factors have yet been identified, though the incidence of vCJD is higher in the north of Great Britain than in the south [55] . An analysis of a cluster of 5 cases in Leicestershire indicates that these patients were probably infected by beef that had been cross-contaminated with neural tissue in the local butchers' shops [56] .
Several attempts have been made to estimate the number of people who may be currently incubating the disease, based on the current number of cases or the exposure to infected bovine products. The median incubation period of the disease and uncertainty over the efficiency of transmission of BSE to humans by consumption of infected bovine products has lead to a range of estimates of between 80 and 140,000 cases by the year 2040 [57] [58] [59] . However the uncertainty may be even greater than that implied by the published ranges if some key assumptions are incorrect [60] .
Other peripherally transmitted human TSEs have long median incubation periods. Kuru, a human TSE trans-mitted by cannibalistic funeral rites, demonstrated a median incubation period of 13 to 15 years with a range of between 4.5 and more than 40 years. Iatrogenic CJD transmitted by cadaveric pituitary growth hormones has a median incubation period of 12 years with a range of 4.5 to 25 years [59] . Two considerations suggest the median incubation period of vCJD could well be longer than this. In experimental animals, transmission of a TSE across a species barrier typically leads to a prolongation in the incubation period. In addition, the investigation into the Leicestershire cluster concluded that exposure may have occurred during the early 1980s [56] , suggesting that some of the clinical cases of vCJD we are currently seeing may represent people exposed during the earliest phase of the BSE epidemic. This would imply that BSE is more easily transmissible and with a relatively longer incubation period than previously thought. Taking all information into account, it is likely that incubation periods in patients infected by BSE-infected meat products are likely to be as long as or longer than those seen in kuru and iatrogenic CJD.
Finally, a single nucleotide polymorphism at codon 129 of the prion gene encoding for methionine or valine has been shown to have an important influence on age of onset, duration, and disease phenotype in familial human TSE, and on susceptibility and incubation periods in sporadic and iatrogenic CJD [61] [62] [63] . A recent analysis of patients with kuru found early clinical involvement of methionine homozygous patients, whereas most valine homozygous and valine heterozygous patients either developed clinical disease after a very long incubation period (>20 years) or survived the epidemic [64] . All cases of vCJD have thus far occurred in individuals who are methionine homozygous at codon 129 of the PrP gene. The aforementioned data suggest that cases are yet to occur in valine homozygous or heterozygous patients. Finally, murine studies indicate that there are major genetic effects on incubation time independent of the PrP gene itself and suggest further caution should be employed in interpreting estimates of a vCJD epidemic based on an assumption of a monophasic disease [65•].
In the absence of a peripheral blood assay to evaluate the number of individuals who may be in the preclinical phase of disease, retrospective and prospective studies of tonsil and appendix specimens removed during routine surgery in the UK for PrP Sc accumulation have been established [66] . An initial series of 3000 cases reported no positive cases [67] . However these studies are limited by the relatively small sample size thus far and the fact that it is not known at what stage during the incubation period PrP Sc may be detectable in the peripheral lymphoid tissue in vCJD. Therefore although positive findings would have been worrying, negative findings do not significantly alter the range of possible cases at this stage [68] .
In the UK, approximately 5% of the population act as blood donors at any one time. If one accepts the limitations of the current mathematical models, an upper-limit estimate of 7,000 UK blood donors (out of 3 million, or 1/500) could currently be in the preclinical phase of disease.
Strategies to reduce the risk of transmission
Given the uncertainty surrounding the number of people currently incubating vCJD and the potential transmissibility of the disease by blood transfusion, blood transfusion services have sought to apply precautionary policies in an attempt to reduce the risk of infection. Authorities in several countries have implemented a policy of deferral of donors who have spent more than a cumulative total of 6 months in the UK between 1980 and 1996. In the United States, the FDA has recently proposed extension of these deferral criteria to include anyone who, since 1980, has lived or traveled in Europe for more than 5 years or who has spent more than a cumulative total of 3 months in the UK. These criteria are based on estimates of maximum achievable risk reduction for tolerable reduction in the blood donor base (usually 3-5%). In the UK there are no clear high-risk demographic groups. A policy of deferral of donors who themselves have received blood transfusion or who have undergone surgery or invasive medical procedures is under consideration, but whether such donors are at higher risk of vCJD than the general UK population is unknown and the impact on the donor base would be substantial. UK blood transfusion services are considering sourcing clinical plasma and cryoprecipitate from outwith the country. However it is unlikely that it will be feasible to source the estimated 2.5 million red cell and platelet concentrates used for UK patients per annum from elsewhere, though sourcing these components for groups of "most vulnerable" patients such as neonates and other children born since 1996 may be feasible. For most patients, development of a donor-screening assay or new component processing steps represents the most feasible way to reduce the risk of disease transmission.
The development of diagnostic assays
In the absence of a conventional immune response to or detectable DNA associated with the infective agent in TSEs, conventional serologic and molecular approaches to the development of peripheral blood diagnostic or screening assays are problematic. Some nonspecific peripheral blood markers of central nervous system damage have been assessed, with one promising report of a positive enzyme immunoassay for S100 in clinical CJD [69] . It seems unlikely, however, that such assays will ever be able to detect early infection. There has been limited research into the possible impact of CJD on the hematopoietic and immune systems. A recent paper has demonstrated decreased expression of erythroid differentiation-related factor (EDRF) in the bone marrow and peripheral blood of scrapie-infected sheep and rodents and of BSE-infected cattle [70] , suggesting both that this transcript itself might prove a useful marker of early disease and also that a search for other subtle alterations in peripheral blood cell phenotype might be of value. It is known that PrP C is expressed by mononuclear cells and platelets in humans and is present in the plasma [71, 72] . A recent study using dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) has demonstrated increased levels of PrP in the plasma of patients with CJD and other neurodegenerative diseases [73] . Many groups are working on the development of assays to detect levels of PrP Sc as low as 1 pg/mL [74, 75] in the presence of an excess of PrP C estimated to be in the range of 10 to 300 ng/mL [72, 73] . Only one monoclonal antibody has been produced that appears to discriminate between PrP C and PrP Sc , but this is not generally used in immunodetection systems [42•,76] . It is possible that alternative ligands could be used in detection systems. For example a recent study has demonstrated high affinity between plasminogen and PrP Sc [77] . Physicochemical properties such as insolubility in non-ionic detergents and partial resistance to proteinase K digestion can also be used to discriminate between PrP C and PrP Sc . Optimization of the Western blot has driven down the threshold of detection of PrP Sc to the order of approximately 100 pg/mL [78] . A number of other assay systems are currently being explored to increase the sensitivity of detection. A competitive fluorescence capillary electrophoretic assay has been reported to have sensitivity of between 5 and 100 ng/mL and has been used to detect PrP Sc in the peripheral blood of scrapie-infected sheep [79] . Conformation-dependent DELFIA is reported to have a sensitivity of 5 pg/mL for purified material but 1 to 2 ng/mL in the presence of tissue [80] . A double-antibody DELFIA has also been reported to have sensitivity in the order of 100 pg/mL, and a modification of this approach using protocadherin-2, a cellular receptor for PrP, is under development [81] . Other approaches under investigation include ultraviolet fluorescence spectroscopy (sensitivity 3 µg/mL) [82], confocal laser spectroscopy (sensitivity 100 pg/mL) [83] , and immuno-polymerase chain reaction (PCR). Brown [42•] has raised serious concerns over the possibility that PrPres may be below the threshold of detection of any of the current generation of assay systems. However even if the difficulties with assay sensitivity are overcome, a number of serious questions remain regarding the issues of assay validation, confirmatory tests, lack of standardized reagents, practicality for large-scale screening, and donor counseling. A first generation assay could have a significant negative impact on donor recruitment and re-tention irrespective of the frequency of assay positivity or donor deferral.
Blood component and plasma processing
The UK and several other European countries have implemented universal leukodepletion to try to reduce the risk of transmission of vCJD by blood components. This policy is based on evidence of early involvement of the immune system in the pathogenesis of peripherally transmitted TSEs and data from experimental animal models demonstrating a 4-to 5-fold higher concentration of infectivity in the buffy coat (containing the leukocytes and platelets) than in the plasma, with no detectable infectivity in the red cells [see "Peripheral Blood Infectivity"]. Whole blood and red cell concentrate leukofiltration removes approximately 3 to 4 log 10 leukocytes and 1 to 2 log 10 platelets, whereas leukofiltration of platelet concentrates removes only the leukocytes [84]. Recent work shows no evidence of selective removal of leukocyte subsets or of significant microvesiculation or fragmentation of cells as a result of the filtration process. Further, reductions in PrP are commensurate with those predicted from the reduction in leukocytes, platelets, and plasma during component processing [Rider et al. and Krailadsiri et al. manuscripts in preparation]. Having said this, there is no evidence that universal leukodepletion reduces the risk of transmission of vCJD, and preliminary results in rodent models indicate that plasma infectivity was not reduced by leukocyte filtration or high-speed centrifugation [43] [44] [45] [46] . This suggests that PrP Sc in plasma is not cell or microvesicle associated.
Several groups have investigated the potential impact of plasma fractionation on plasma infectivity. A theoretical analysis based on the known physicochemical characteristics of PrP Sc suggested that a number of processing steps might lead to significant reductions in infectivity [85] . Rodent models showed further reduction in infectivity in Cohn fraction I to III (the source of factors VIII and IX and immunoglobulin preparations) and no detectable infectivity in fractions IV and V (the source of albumin) compared with plasma [43] [44] [45] [46] . Studies have been carried out to investigate the impact of a number of fractionation steps on a 263k hamster scrapie spike and detection of PrP Sc by Western blot [86,87•]. Reductions in PrP Sc in the order of 3 to 4 log 10 were demonstrated by the cold ethanol precipitation, ion exchange, and depth filtration steps in the FVIII and IX, immunoglobulin and albumin processes. Whether these steps are additive is unclear at present. A recent study has provided data that demonstrates a good correlation between levels of PrP Sc on Western blot and infectivity in these kinds of plasma fractionation studies [88] . Finally nanofiltration at 15 nm should provide an effective method of removing PrP Sc from plasma products and has been implemented by one country.
A number of agents, including Congo Red and its analogues [89] , porphyrins and phthalocyanines [90] , lysosomotropic agents, cysteine protease inhibitors [91] and synthetic peptides [92] have demonstrated inhibitory activity against PrP Sc accumulation in in vitro cell-free or cell culture systems. Several drugs, including steroids, amphoteracin-B [93] , doxorubicin, and dapsone [94] have been shown to inhibit peripheral transmission of TSEs in animal models . Glycosaminoglycans such as pentosan polysulfate are promising but have adverse effects on the hemostatic and immune systems [95] .
Conclusions
Profound uncertainty remains about the risk of transmission of vCJD posed by blood components and products. Blood transfusion services are obliged to implement precautionary policies wherever possible but must balance these against the potential negative impact on the security or safety of the blood supply. Work continues on the development of diagnostic assays, the evaluation of the possible benefits of a variety of blood component and plasma processing steps, and the possibility of developing prophylactic or therapeutic agents that may be useful in the treatment of blood transfusion recipients or other at-risk groups of patients.
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